News Image

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Provided By GlobeNewswire

Last update: Jul 16, 2025

BOSTON, July 16, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided a clinical update on its most advanced asset, CUE-101, representative of the CUE-100 series.

Read more at globenewswire.com

CUE BIOPHARMA INC

NASDAQ:CUE (8/1/2025, 8:00:00 PM)

After market: 0.7225 -0.01 (-1.99%)

0.7372

-0.01 (-1.79%)



Find more stocks in the Stock Screener

CUE Latest News and Analysis

Follow ChartMill for more